Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Igc Pharma Inc (IGC)

Igc Pharma Inc (IGC)
0.2809 x 5 0.2900 x 4
Post-market by (Cboe BZX)
0.2834 -0.0003 (-0.11%) 04/21/25 [NYSE Arca]
0.2809 x 5 0.2900 x 4
Post-market 0.2900 +0.0066 (+2.33%) 19:28 ET
Quote Overview for Mon, Apr 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.2786
Day High
0.3000
Open 0.2800
Previous Close 0.2837 0.2837
Volume 164,400 164,400
Avg Vol 242,150 242,150
Stochastic %K 65.85% 65.85%
Weighted Alpha -42.77 -42.77
5-Day Change +0.0039 (+1.40%) +0.0039 (+1.40%)
52-Week Range 0.2525 - 0.6330 0.2525 - 0.6330
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,607
  • Shares Outstanding, K 79,685
  • Annual Sales, $ 1,350 K
  • Annual Income, $ -13,000 K
  • EBIT $ -8 M
  • EBITDA $ -8 M
  • 60-Month Beta 1.45
  • Price/Sales 16.67
  • Price/Cash Flow N/A
  • Price/Book 3.53
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.11
  • Most Recent Earnings $-0.02 on 02/14/25
  • Next Earnings Date 02/12/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 491.87% ( +31.15%)
  • Historical Volatility 58.67%
  • IV Percentile 50%
  • IV Rank 41.89%
  • IV High 944.17% on 08/07/24
  • IV Low 165.85% on 10/21/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 9
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,997
  • Open Int (30-Day) 1,981

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.02
  • Number of Estimates 1
  • High Estimate -0.02
  • Low Estimate -0.02
  • Prior Year -0.04
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2525 +12.24%
on 04/07/25
Period Open: 0.3230
0.3247 -12.72%
on 03/26/25
-0.0396 (-12.26%)
since 03/21/25
3-Month
0.2525 +12.24%
on 04/07/25
Period Open: 0.3434
0.3700 -23.41%
on 01/22/25
-0.0600 (-17.47%)
since 01/21/25
52-Week
0.2525 +12.24%
on 04/07/25
Period Open: 0.4900
0.6330 -55.23%
on 05/01/24
-0.2066 (-42.16%)
since 04/19/24

Most Recent Stories

More News
IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

Industry Veterans Bring Deep Strategic Experience to Guide Alzheimer's Clinical Expansion and Commercial Strategy

IGC : 0.2834 (-0.11%)
IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

POTOMAC, MARYLAND / ACCESS Newswire / April 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the expansion of its ongoing Phase 2 CALMA clinical trial with...

IGC : 0.2834 (-0.11%)
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

POTOMAC, MARYLAND / ACCESS Newswire / April 1, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its Phase 2 clinical trial, CALMA, evaluating IGC-AD1 for the treatment of agitation...

IGC : 0.2834 (-0.11%)
IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

- IGC-AD1 Could Offer Safer Alternative to Existing Sleep Medications for Alzheimer's -

IGC : 0.2834 (-0.11%)
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

POTOMAC, MD / ACCESS Newswire / March 20, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 CALMA trial for IGC-AD1 with the addition...

IGC : 0.2834 (-0.11%)
IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida

POTOMAC, MARYLAND / ACCESS Newswire / March 17, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the addition of a new trial site at BayCare's St. Anthony's Hospital...

IGC : 0.2834 (-0.11%)
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25"

POTOMAC, MARYLAND / ACCESS Newswire / March 12, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Ascendiant Capital Markets has issued a coverage report...

IGC : 0.2834 (-0.11%)
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the “Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results”

POTOMAC, MARYLAND / ACCESS Newswire / March 10, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Alliance Global Partners (AGP) has issued an analyst update...

IGC : 0.2834 (-0.11%)
IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection

POTOMAC, MD / ACCESS Newswire / March 4, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced an advancement in its Artificial Intelligence ("AI") platform with the development...

IGC : 0.2834 (-0.11%)
IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market

- New science-backed formulations designed to support cellular health, energy metabolism, and cognitive function -

IGC : 0.2834 (-0.11%)

Business Summary

IGC Pharma Inc. develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. IGC Pharma Inc., formerly known as India Globalization Capital Inc., is based in POTOMAC, Md....

See More

Key Turning Points

3rd Resistance Point 0.3175
2nd Resistance Point 0.3087
1st Resistance Point 0.2961
Last Price 0.2834
1st Support Level 0.2747
2nd Support Level 0.2659
3rd Support Level 0.2533

See More

52-Week High 0.6330
Fibonacci 61.8% 0.4876
Fibonacci 50% 0.4428
Fibonacci 38.2% 0.3979
Last Price 0.2834
52-Week Low 0.2525

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro